Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 2 Results

  1. 1
    782786

    Comparison of IPCS and Copper-7 bleeding patterns during the first 12 months of use.

    PIZARRO E; GOMEZ-ROGERS C

    In: Mishell, D.R., Jr., and Martinez-Manautou, J., eds. Clinical experience with the progesterone uterine therapeutic system. (Proceedings of the Acapulco Workshop, Acapulco, Mexico, October 15-16, 1976) Princeton, New Jersey, Excerpta Medica, 1978. p. 99-103

    In order to compare the efficacy and acceptability of the Progestasert progesterone-releasing IUD and the Gravigard Copper-7 device, 295 parous women randomly received the progesterone device (146) or the copper device (149). Follow-up examinations took place at 1, 3, 6, and 12 months postinsertion. It was found that event rates did not differ significantly between the progesterone (1569 women-months) and the copper (1558 woman-months) devices. Greater pain on insertion (23.3% versus 15.4%), less metrorrhagia (7.5% versus 13.4%), and higher continuation rates after 1 year of use (87.2% versus 84.6%) were associated with the progesterone device. A flow decrease of 27.2% and increase of more than 22.3% was associated with the Copper-7. Duration of menstruation was not significantly different between the 2 groups, but the progesterone IUD users had more days of "spotting." In both groups, duration of menstruation increased by the end of the study year for a large number of women. This was significant only in Copper-7 users.
    Add to my documents.
  2. 2
    782768

    Philosophy of testing of the intrauterine progesterone contraceptive system.

    PHARRISS BB

    In: Mishell, D.R., Jr., and Martinez-Manautou, J., eds. Clinical experience with the progesterone uterine therapeutic system. (Proceedings of the Acapulco Workshop, Acapulco, Mexico, October 15-16, 1976.) Princeton, New Jersey, Excerpta Medica, 1978. p. 13-17

    There were 7323 first insertions, and 4177 subsequent insertions of the Progestasert intrauterine progesterone contraceptive (IPCS) in women all over the world. To obtain a diversity of testing situations private and public clinics were employed to evaluate the contraceptive efficiency and acceptability of the IPCS. 75% of patients were parous, and average exposure was 10 months. Portions of the study were monitored by WHO and by international and indigenous pharmaceutical companies. Results from the study suggest that consistency in pregnancy rate and in expulsion rates have been established. Removals are more likely to be cultural than physiological in nature. Up to now there are no indications that unforeseen complications due to the IPCS might be occurring.
    Add to my documents.